Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tourmaline Bio, Inc. - Common Stock (NQ: TRML )

22.72 -1.28 (-5.33%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tourmaline Bio, Inc. - Common Stock

< Previous 1 2 Next >
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Present at Upcoming Investor Conferences
From Tourmaline Bio, Inc.
Via GlobeNewswire
TRML Stock Earnings: Tourmaline Bio Reported Results for Q4 2023
Tourmaline Bio just reported results for the fourth quarter of 2023. 
Via InvestorPlace
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Present at Upcoming Investor Conferences
From Tourmaline Bio, Inc.
Via GlobeNewswire
TRML Stock Earnings: Tourmaline Bio Beats EPS for Q2 2024
TRML stock results show that Tourmaline Bio beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
From Tourmaline Bio, Inc.
Via GlobeNewswire
TRML Stock Earnings: Tourmaline Bio Beats EPS for Q1 2024
TRML stock results show that Tourmaline Bio beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
From Avalo Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-than-expected second-quarter revenue and issued FY24 guidance. 
Via Benzinga
Dow Jumps 200 Points; US Weekly Jobless Claims Fall
U.S. stocks traded higher this morning, with the Dow Jones index gaining around 200 points on Thursday. Following the market opening Thursday, the Dow traded up 0.52% to 39,718.37 while the NASDAQ rose... 
Via Benzinga
Topics Stocks
Exposures US Equities
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
Investors saw Chugai's experimental drug as a potential rival to Argenx's approved medicine, Vyvgart. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Five Below Posts Q4 Results, Joins LexinFintech And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Announces Pricing of Public Offering of Common Stock
From Tourmaline Bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Tourmaline Bio Announces Proposed Public Offering of Common Stock
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)
From Tourmaline Bio, Inc.
Via GlobeNewswire
TDCX Receives Preliminary Non-binding Proposal Letter, Joins Pure Storage, Dyne Therapeutics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Nasdaq Composite falling around 150 points on Wednesday. Shares of TDCX Inc. (NYSE: TDCX) rose sharply during Wednesday’s session after it disclosed receiving a... 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.